Piramal Pharma Solutions (PPS), the Contract Development and Manufacturing Organization (CDMO) business of Piramal Pharma Limited, is adding a 4.3 MWp ground-mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, UK. The solar installation will supply approximately 3,950 MWh of renewable electricity annually once operational, meeting around 22% of the facility’s yearly electricity demand. The project is being developed under a Power Purchase Agreement (PPA) with Alight UK BTM1 Limited, a solar developer and independent power producer.
The plant will comprise approximately 6,200 solar panels spread across 16 acres. Based on the project’s expected generation, the installation will produce enough electricity to power around 1,460 UK homes each year. Operations at the solar facility are scheduled to begin in the first quarter of 2027. Piramal Pharma Solutions said the project will support its efforts to reduce emissions, strengthen energy resilience and increase the use of renewable electricity at its manufacturing operations.
Over a 25-year period, the solar plant is expected to help Morpeth avoid an estimated 20,000 tonnes of carbon dioxide equivalent (tCO₂e). The project forms part of Piramal Pharma’s broader decarbonisation and sustainability programme across its global operations.
“At Piramal Pharma Solutions, we integrate sustainability principles into every operation and decision across our global network,” said Frank Bugg, Senior Vice President, UK & Europe Operations and Managing Director, Piramal Pharma Solutions. “We are excited to advance our commitment to decarbonization and renewable energy with our partner Alight, bringing new value to our customers and shareholders worldwide.”
Rob Stait, Managing Director, Behind the Meter at Alight, said, “Businesses across the UK are looking for practical ways to lower emissions, strengthen energy resilience, and manage long-term energy costs. This project with Piramal Pharma shows how onsite solar can deliver all three.”
The ground-mounted solar plant will provide electricity directly to the Morpeth facility, supporting the site’s energy requirements through renewable generation. The project is also expected to improve the resilience of the facility’s electricity supply while reducing its dependence on conventional power sources.
Piramal Pharma Solutions operates an integrated network of development and manufacturing facilities across North America, Europe and Asia. The company provides services covering drug discovery, pharmaceutical and process development, clinical trial supplies, commercial APIs and finished dosage forms.
Its specialised capabilities include development and manufacturing of highly potent APIs, antibody-drug conjugates, sterile fill/finish, peptide products and potent solid oral drug products. PPS also provides development and manufacturing services for biologics, including vaccines and gene therapies, through Yapan Bio Private Limited.
Piramal Pharma Limited operates 17 global development and manufacturing facilities and has a distribution network covering more than 100 countries. Its businesses include Piramal Pharma Solutions, Piramal Critical Care and Piramal Consumer Healthcare. Its associate company AbbVie Therapeutics India Private Limited is a joint venture between AbbVie and Piramal Pharma and operates in the Indian ophthalmology market.
